Streetbeat News

Price Targets

WEC

Mizuho analyst Anthony Crowdell has maintained a Buy rating on WEC Energy Group (NYSE:WEC) but has reduced the price target from $88 to $86.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 5:01 pm

JPM

JPMorgan Chase (NYSE:JPM) has received predominantly positive analyst ratings in the last 3 months, with 6 somewhat bullish and 1 indifferent rating. The average 12-month price target is $201.43, with a high of $243.00 and a low of $170.00. Notably, the average price target has increased by 3.07% over the past month. Analysts from firms such as Oppenheimer, Piper Sandler, BMO Capital, and Morgan Stanley have raised their price targets, indicating a positive sentiment towards JPM's market performance and financial health.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

NICE

Recent reports from 8 analysts in the last quarter show a generally positive sentiment towards NICE (NASDAQ:NICE), with 7 somewhat bullish and 1 indifferent rating. The average 12-month price target is $254.38, with a high of $343.00 and a low of $190.00. Over the past month, the average price target has increased by 7.11%. Analysts from firms like JMP Securities, RBC Capital, Morgan Stanley, Oppenheimer, and DA Davidson have maintained or lowered their price targets, with ratings ranging from 'Market Outperform' to 'Neutral'. NICE is an enterprise software company with a focus on customer engagement and financial crime and compliance solutions. Despite a lower revenue growth rate compared to industry peers, NICE has shown strong financial performance with a high net margin of 15.36%, an ROE of 2.89%, and an ROA of 1.88%, along with a low debt-to-equity ratio of 0.23.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

HBAN

RBC Capital has reaffirmed its Outperform rating on Huntington Bancshares (NASDAQ:HBAN) and increased its price target from $12.00 to $15.00. HBAN's stock is currently up 1.09% at $13.00, and the new target suggests a potential upside of 15.38%. Huntington Bancshares is a regional bank offering a range of financial services across eight Midwestern states.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

AFRM

Morgan Stanley has downgraded Affirm Holdings (NASDAQ:AFRM) to Underweight with a new price target of $20.00, up from the previous $15.00. Affirm's shares have fallen 2.77% to $42.75, and the new target suggests a potential 53.22% decrease in share price. Affirm provides a digital commerce platform, mainly generating revenue in the U.S.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

CMPO

JP Morgan has downgraded CompoSecure (NASDAQ:CMPO) from its previous rating to Neutral, adjusting the price target from $7.00 to $6.00. CompoSecure's shares have fallen 3.87% in the last 24 hours to $4.72. The new price target suggests a potential upside of 27.12% from the current price. CompoSecure specializes in premium financial cards and digital security platforms.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

TROX

BMO Capital has upgraded Tronox Holdings (NYSE:TROX) to Outperform with a new price target of $18.00, up from the previous $11.00. Tronox's shares have risen 8.09% in the last 24 hours to $14.69. The new price target suggests a potential upside of 22.53%. Tronox is a vertically integrated TiO2 pigment manufacturer with operations across various regions and serves multiple industries.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

RUN

Goldman Sachs has reaffirmed its Buy rating on Sunrun (NASDAQ:RUN) and increased its price target from $17.00 to $20.00. Despite this, Sunrun's shares have fallen 2.42% to $18.18 in the last 24 hours. The new price target suggests a potential upside of 10.01% from the current price. Sunrun specializes in residential solar energy systems in the U.S., offering design, installation, and maintenance services.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

ARGX

Stifel has reaffirmed its Buy rating on argenx (NASDAQ:ARGX) and increased its price target from $557.00 to $560.00. Despite the positive outlook, argenx shares have fallen 1.05% in the last 24 hours to $458.16. The new price target suggests a potential upside of 22.23%. Argenx specializes in antibody engineering for rare autoimmune diseases, with its drug Vyvgart approved in the U.S., Europe, and Japan.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:00 pm

EXC

Mizuho analyst Paul Fremont has maintained a Neutral rating on Exelon (NASDAQ:EXC) but has reduced the price target from $40 to $36.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:59 pm